GPT-Rosalind is OpenAI's first domain-specific model, built for drug discovery and life sciences—and it's not for everyone.

Enterprise technology vendors are racing to make AI work against the structured and relational data inside databases, data ...

Credit: VentureBeat made with OpenAI GPT-Image-1.5 The journey from a laboratory hypothesis to a pharmacy shelf is one of the ...

OpenAI is framing GPT-Rosalind as a tool to compress the timeline from scientific idea to clinical evidence. The company ...

Kumo has unveiled KumoRFM-2, a next-generation foundation model designed specifically for structured enterprise data—marking ...

FEATURE: Most customers don't need the biggest baddest models, just ones that work, are cheap, and won't pirate their ...

By Juby Babu April 16 - OpenAI on Thursday introduced an artificial intelligence model touting increased biology knowledge ...

Intelligence without integrity is just sophisticated risk. To build AI that lasts, you have to apply zero-trust principles to ...

Getting a drug from initial target discovery to U.S. regulatory approval takes between 10 and 15 years on average. Most of ...

The next important milestone for AI research is to automate model development. Every advance in reasoning, language, and perception is, in some sense, a step toward that goal. However, the path to ...

The GPT-Rosalind model is designed to accelerate biological research and drug discovery. View on euronews ...

Rosalind, a biological language model for target discovery and genomics. Currently only available for US corporate customers.